Cell Therapeutics, Inc. announced today that it began a rolling submission of a New Drug Application to the U.S. FDA for pixantrone to treat relapsed or refractory aggressive non-Hodgkin's lymphoma. CTI expects to complete the submission this quarter and will request priority review which if granted could lead to an approval decision from the FDA in Q4 2009.
The details can be read here.
No comments:
Post a Comment